vs

Side-by-side financial comparison of NewAmsterdam Pharma Co N.V. (NAMS) and FiscalNote Holdings, Inc. (NOTE). Click either name above to swap in a different company.

FiscalNote Holdings, Inc. is the larger business by last-quarter revenue ($22.2M vs $19.1M, roughly 1.2× NewAmsterdam Pharma Co N.V.). On growth, NewAmsterdam Pharma Co N.V. posted the faster year-over-year revenue change (740.1% vs -24.7%). FiscalNote Holdings, Inc. produced more free cash flow last quarter ($-1.9M vs $-37.8M).

Kite Pharma, Inc. is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in Santa Monica, California, it was acquired by Gilead Sciences in 2017.

FiscalNote Holdings, Inc., or commonly FiscalNote, is a publicly traded software, data, and media company headquartered in Washington, D.C. The company was founded by Timothy Hwang, Gerald Yao, and Jonathan Chen in 2013. FiscalNote provides software tools, platforms, data services, and news through the FiscalNote Government Relationship Management (GRM) service, its core product. The company also uses an artificial intelligence platform to analyze proposed U.S. legislation based on key phrase...

NAMS vs NOTE — Head-to-Head

Bigger by revenue
NOTE
NOTE
1.2× larger
NOTE
$22.2M
$19.1M
NAMS
Growing faster (revenue YoY)
NAMS
NAMS
+764.7% gap
NAMS
740.1%
-24.7%
NOTE
More free cash flow
NOTE
NOTE
$35.8M more FCF
NOTE
$-1.9M
$-37.8M
NAMS

Income Statement — Q2 FY2025 vs Q4 FY2025

Metric
NAMS
NAMS
NOTE
NOTE
Revenue
$19.1M
$22.2M
Net Profit
$-17.4M
Gross Margin
Operating Margin
-186.1%
-83.7%
Net Margin
-90.7%
Revenue YoY
740.1%
-24.7%
Net Profit YoY
55.5%
EPS (diluted)
$-0.15
$-2.81

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NAMS
NAMS
NOTE
NOTE
Q4 25
$22.2M
Q3 25
$22.4M
Q2 25
$19.1M
$23.3M
Q1 25
$27.5M
Q4 24
$12.8M
$29.5M
Q3 24
$29.1M
$29.4M
Q2 24
$29.2M
Q1 24
$32.1M
Net Profit
NAMS
NAMS
NOTE
NOTE
Q4 25
Q3 25
$-24.9M
Q2 25
$-17.4M
$-13.3M
Q1 25
$-4.3M
Q4 24
$-92.2M
Q3 24
$-16.6M
$-14.9M
Q2 24
$-12.8M
Q1 24
$50.6M
Operating Margin
NAMS
NAMS
NOTE
NOTE
Q4 25
-83.7%
Q3 25
-43.4%
Q2 25
-186.1%
-31.9%
Q1 25
-50.0%
Q4 24
-338.5%
-19.4%
Q3 24
-85.9%
-23.1%
Q2 24
-27.2%
Q1 24
-35.6%
Net Margin
NAMS
NAMS
NOTE
NOTE
Q4 25
Q3 25
-110.8%
Q2 25
-90.7%
-57.0%
Q1 25
-15.4%
Q4 24
-721.7%
Q3 24
-57.2%
-50.7%
Q2 24
-43.6%
Q1 24
157.6%
EPS (diluted)
NAMS
NAMS
NOTE
NOTE
Q4 25
$-2.81
Q3 25
$-1.73
Q2 25
$-0.15
$-0.08
Q1 25
$-0.03
Q4 24
$-0.91
$1.88
Q3 24
$-0.18
$-1.33
Q2 24
$-0.09
Q1 24
$0.37

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NAMS
NAMS
NOTE
NOTE
Cash + ST InvestmentsLiquidity on hand
$739.2M
$26.3M
Total DebtLower is stronger
$128.4M
Stockholders' EquityBook value
$778.5M
$62.0M
Total Assets
$815.1M
$255.1M
Debt / EquityLower = less leverage
2.07×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NAMS
NAMS
NOTE
NOTE
Q4 25
$26.3M
Q3 25
$31.2M
Q2 25
$739.2M
$38.5M
Q1 25
$46.3M
Q4 24
$834.2M
$34.6M
Q3 24
$422.7M
$32.7M
Q2 24
$37.7M
Q1 24
$43.6M
Total Debt
NAMS
NAMS
NOTE
NOTE
Q4 25
$128.4M
Q3 25
$131.5M
Q2 25
$116.7M
Q1 25
$118.0M
Q4 24
$147.1M
Q3 24
$152.2M
Q2 24
$145.9M
Q1 24
$153.0M
Stockholders' Equity
NAMS
NAMS
NOTE
NOTE
Q4 25
$62.0M
Q3 25
$75.5M
Q2 25
$778.5M
$95.1M
Q1 25
$98.7M
Q4 24
$757.5M
$97.8M
Q3 24
$378.9M
$98.5M
Q2 24
$106.9M
Q1 24
$106.1M
Total Assets
NAMS
NAMS
NOTE
NOTE
Q4 25
$255.1M
Q3 25
$273.9M
Q2 25
$815.1M
$288.3M
Q1 25
$299.7M
Q4 24
$864.6M
$326.2M
Q3 24
$439.2M
$337.9M
Q2 24
$346.3M
Q1 24
$357.8M
Debt / Equity
NAMS
NAMS
NOTE
NOTE
Q4 25
2.07×
Q3 25
1.74×
Q2 25
1.23×
Q1 25
1.20×
Q4 24
1.50×
Q3 24
1.54×
Q2 24
1.36×
Q1 24
1.44×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NAMS
NAMS
NOTE
NOTE
Operating Cash FlowLast quarter
$-37.7M
$-279.0K
Free Cash FlowOCF − Capex
$-37.8M
$-1.9M
FCF MarginFCF / Revenue
-197.2%
-8.7%
Capex IntensityCapex / Revenue
0.5%
7.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-119.7M
$-18.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NAMS
NAMS
NOTE
NOTE
Q4 25
$-279.0K
Q3 25
$-8.3M
Q2 25
$-37.7M
$-6.2M
Q1 25
$3.3M
Q4 24
$-37.5M
$-1.3M
Q3 24
$-12.5M
$-3.0M
Q2 24
$-3.7M
Q1 24
$2.7M
Free Cash Flow
NAMS
NAMS
NOTE
NOTE
Q4 25
$-1.9M
Q3 25
$-10.4M
Q2 25
$-37.8M
$-7.7M
Q1 25
$1.3M
Q4 24
$-37.5M
$-3.4M
Q3 24
$-12.6M
$-5.4M
Q2 24
$-6.5M
Q1 24
$1.0M
FCF Margin
NAMS
NAMS
NOTE
NOTE
Q4 25
-8.7%
Q3 25
-46.2%
Q2 25
-197.2%
-33.0%
Q1 25
4.7%
Q4 24
-293.5%
-11.4%
Q3 24
-43.2%
-18.4%
Q2 24
-22.1%
Q1 24
3.3%
Capex Intensity
NAMS
NAMS
NOTE
NOTE
Q4 25
7.4%
Q3 25
9.3%
Q2 25
0.5%
6.4%
Q1 25
7.2%
Q4 24
0.0%
6.8%
Q3 24
0.3%
8.3%
Q2 24
9.4%
Q1 24
5.3%
Cash Conversion
NAMS
NAMS
NOTE
NOTE
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
0.05×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

NAMS
NAMS

Segment breakdown not available.

NOTE
NOTE

Subscription$21.2M95%
Advisory Advertising And Other$1.0M5%

Related Comparisons